(Q54539963)

31 May 2018

title

VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. (English)

1 reference

31 May 2018

0 references

Yosuke Doi

1

1 reference

31 May 2018

Masakazu Yashiro

2

1 reference

31 May 2018

Nobuya Yamada

3

1 reference

31 May 2018

Ryosuke Amano

4

1 reference

31 May 2018

Satoru Noda

5

1 reference

31 May 2018

Kosei Hirakawa

6

1 reference

31 May 2018

publication date

30 December 2011

1 reference

31 May 2018

Annals of Surgical Oncology

published in

1 reference

31 May 2018

volume

19

1 reference

31 May 2018

issue

8

1 reference

31 May 2018

page(s)

2733-2743

1 reference

31 May 2018

Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

VEGF-RII influences the prognosis of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Expression of vascular endothelial growth factors A and C in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Expression of vascular endothelial growth factor receptors in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

A new mathematical model for relative quantification in real-time RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Pathways for aberrant angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Evaluation of Novel Antimouse VEGFR2 Antibodies as Potential Antiangiogenic or Vascular Targeting Agents for Tumor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

Pancreatic cancer growth is inhibited by blockade of VEGF-RII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2181-6

10.1245/S10434-011-2181-6

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

Dimensions Publication ID

1032507936

0 references

1 reference

31 May 2018